TP53 and cancer: Cancers that inactivate the p53 tumor suppressor, either through mutations or deletions in the p53 gene itself or indirectly via deregulation of upstream pathways, exhibit increased aggressiveness and resistance to various therapies.[38] Therefore, to circumvent these kinds of cancers, novel strategies to deal with cellular p53 activity en masse are required.